The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

Diabetologia

Volumn 48, Issue 1, 2005, Pages 83-95

  Tan, G D ^a   Fielding, B A ^a   Currie, J M ^a   Humphreys, S M ^a   Desage M ^b,c   Frayn, K N ^a   Laville, M ^b,c   Vidal, H ^b   Karpe, F ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITÉ LYON 1   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Human metabolism; Insulin resistance; Integrative physiology; NEFA; Postprandial metabolism; Systems physiology

Indexed keywords

FATTY ACID; HEXOKINASE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL; TRIPALMITIN;

ADIPOSE TISSUE; ADIPOSE TISSUE BLOOD FLOW; ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC DIET; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATTY ACID METABOLISM; FEMALE; FOREARM BLOOD FLOW; GENE EXPRESSION; HUMAN; LIPID METABOLISM; MALE; MUSCLE BLOOD FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VENOUS BLOOD;

ADIPOSE TISSUE; ADULT; AGED; BIOPSY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; MUSCLE, SKELETAL; PLACEBOS; REGIONAL BLOOD FLOW; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 12944319827     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1619-9     Document Type: Article

References (76)

1. Auwerx J (1999) PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-1049
2. Way JM, Harrington WW, Brown KK et al (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277
3. Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
4. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10
5. Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265-294
6. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI (2000) Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831
7. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA (2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1128
8. Tan GD, Debard C, Tiraby C et al (2003) A "futile cycle" induced by thiazolidinediones in human adipose tissue? Nat Med 9:811-812
9. Finegood DT, McArthur MD, Kojwang D et al (2001) Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029
10. Zhou YT, Grayburn P, Karim A et al (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784-1789
11. Maggs DG, Buchanan TA, Burant CF et al (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185
12. Mayerson AB, Hundal RS, Dufour S et al (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802
13. Hällsten K, Virtanen KA, Lönnqvist F et al (2002) Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485
14. Nolan JJ, Jones NP, Patwardhan R, Deacon LF (2000) Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17:287-294
15. King AB (2000) A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23:557
16. Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947-952
17. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278-284
18. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17:40-47
19. Fonseca V, Rosenstock J, Patwardhan R, Salzman A (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695-1702
20. Miyazaki Y, Mahankali A, Matsuda M et al (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719
21. Bajaj M, Suraamornkul S, Pratipanawatr T et al (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370
22. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605-1611
23. Sakamoto J, Kimura H, Moriyama S et al (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704-711
24. Vu-Dac N, Schoonjans K, Kosykh V et al (1995) Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750
25. Karpe F (2002) Postprandial lipemia-effect of lipid-lowering drugs. Atheroscler Suppl 3:41-46
26. Ghazzi MN, Perez JE, Antonucci TK et al (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46:433-439
27. Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM (1997) Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20:188-193
28. Sunayama S, Watanabe Y, Ohmura H et al (1999) Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 146:187-193
29. Shirai K, Itoh Y, Sasaki H et al (1999) The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35-41
30. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203
31. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818-1820
32. Kobayashi J, Nagashima I, Hikita M et al (1999) Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47:433-439
33. Ranganathan S, Kern PA (1998) Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. J Biol Chem 273:26117-26122
34. Rieusset J, Auwerx J, Vidal H (1999) Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265-271
35. McTernan PG, Harte AL, Anderson LA et al (2002) Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 51:1493-1498
36. Frayn KN, Coppack SW (2001) Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269-279
37. Frayn KN, Coppack SW, Humphreys SM, Whyte PL (1989) Metabolic characteristics of human adipose tissue in vivo. Clin Sci (Lond) 76:509-516
38. Larsen OA, Lassen NA, Quaade F (1966) Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 66:337-345
39. Rådegran G (1999) Limb and skeletal muscle blood flow measurements at rest and during exercise in human subjects. Proc Nutr Soc 58:887-898
40. Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN (2002) Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51:2684-2690
41. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A (2001) Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17-21
42. Auboeuf D, Vidal H (1997) The use of the reverse transcription- competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. Anal Biochem 245:141-148
43. Evans K, Clark ML, Frayn KN (1999) Effects of an oral and intravenous fat load on adipose tissue and forearm lipid metabolism. Am J Physiol 276:E241-E248
44. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
45. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN (1996) Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 91:679-683
46. Jansson PA, Larsson A, Lönnroth PN (1998) Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 28:813-818
47. Issekutz B Jr, Bortz WM, Miller HI, Paul P (1967) Turnover rate of plasma FFA in humans and in dogs. Metabolism 16:1001-1009
48. Bonadonna RC, Groop LC, Zych K, Shank M, DeFronzo RA (1990) Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 259: E736-E750
49. Miyazaki Y, Glass L, Triplitt C et al (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219
50. Auboeuf D, Rieusset J, Fajas L et al (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327
51. Guo Z, Hensrud DD, Johnson CM, Jensen MD (1999) Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 48:1586-1592.
52. Kelly IE, Han TS, Walsh K, Lean ME (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293
53. Virtanen KA, Hällsten K, Parkkola R et al (2003) Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290
54. Frayn KN, Coppack SW, Fielding BA, Humphreys SM (1995) Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Adv Enzyme Regul 35:163-178
55. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS (2002) Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 19:944-948
56. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW (1994) Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43:293-298
57. Damci T, Yalin S, Balci H et al (2004) Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 27:1077-1080
58. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y (2003) PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52:291-299
59. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Invest 113:1582-1588
60. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G (1995) Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166
61. Malmstrom R, Packard CJ, Watson TD et al (1997) Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454-1464
62. Lewis GF, Uffelman KD, Szeto LW, Steiner G (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42:833-842
63. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN (1998) Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 28:1024-1031
64. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN (2002) Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 51:2467-2473
65. Campbell PJ, Carlson MG, Hill JO, Nurjhan N (1992) Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification. Am J Physiol 263:E1063-E1069
66. Zierath JR, Ryder JW, Doebber T et al (1998) Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology 139:5034-5041
67. Kim YB, Ciaraldi TP, Kong A et al (2002) Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51:443-448
68. Meyer MM, Levin K, Grimmsmann T et al (2002) Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 51:2691-2697
69. Cline GW, Petersen KF, Krssak M et al (1999) Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246
70. Kelley DE, Mintun MA, Watkins SC et al (1996) The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705-2713
71. Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248-257
72. Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O (1995) Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96:2639-2645
73. Pendergrass M, Koval J, Vogt C et al (1998) Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387-394
74. Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM (1998) Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107-1113
75. Ducluzeau PH, Perretti N, Laville M et al (2001) Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50:1134-1142
76. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272:28210-28217